Introduction
The human kinome includes 32 non-receptor tyrosine kinases (Manning et al., 2002) that are thought to be key elements of intracellular signalling induced by extracellular stimuli such as cytokines, growth factors and integrins. Indeed, several of them, including the Src family of kinases (SFK), regulate cell growth and migration and play important roles during embryogenesis (Thomas & Brugge, 1997) . c-Abl belongs to this class of tyrosine kinases and is the prototype of a sub-family which includes two members, c-Abl and Arg (Abl-related gene). Both proteins are localised at the cell membrane, actin cytoskeleton and cytosol and cAbl is present in the nucleus as well (cytoplasmic and nuclear c-Abl in this review). ABL1 and ABL2 that encode the human c-Abl and Arg, respectively, are ubiquitously expressed and give rise to the 1a and 1b isoforms. Isoforms 1a originate from an alternative promoter leading to a short amino acid truncation at the N-terminus and omission of the myristoylation site, present in 1b. Abl proteins show a modular organisation similar to that of members of the Src family and are characterised by a unique N-terminus followed by a Src Homology 3 (SH3), a Src Homology 2 (SH2) domain and the catalytic core ( Figure 1 ). However, the short C-terminus tail present in Src is replaced here by a large and unique sequence encoded by the last exon.
This C-terminus includes F-(filamentous) and G-(globular) actin binding domains, nuclear export sequences (NES), and Pro-rich sequences with affinity for SH3-contanining proteins.
In addition, c-Abl contains nuclear localisation signals (NLS) and DNA binding sequences important for nuclear functions (Pendergast, 2002) . Similarly to most tyrosine kinases, the Abl family comprises oncogenic forms that exhibit strict cytoplasmic localisation and a deregulated kinase activity. These include the retroviral oncoprotein v-Abl of the Abelson murine leukaemia virus and the human Bcr-Abl fusion oncoprotein implicated in human chronic myeloid leukaemia and in a subset of lymphocytic leukaemias (Roche & Courtneidge, 1997) .
Abl proteins play important roles in cell homeostasis as determined by gene knock-out experiments in mice. Abl ablation induces pleiotropic defects which cause postpartum mortality as well as lymphopenia and osteoporosis in the surviving animals, while Arg inactivation induces behavioural alterations (Schwartzberg et al., 1991; Tybulewicz et al., 1991) . Interestingly, double gene disruption induces embryonic lethality at E9 indicating that,
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like for the Src members, c-Abl and Arg have important redundant functions during embryogenesis, but unique, specific roles later in development (Koleske et al., 1998) . c-Abl shuttles between the nuclear and cytoplasmic compartments. The role of nuclear c-Abl has been largely documented (Van Etten, 1999) . Indeed it modulates the cellular response induced by DNA damage, and has been implicated in cell growth inhibition and promotion of apoptosis. In contrast, the role of cytoplasmic c-Abl has not been thoroughly described. Genetic and biochemical analysis point to a central role for cytoplasmic c-Abl in morphogenesis and F-actin dynamics (Woodring et al., 2003) . In addition, recent reports suggest a role in signalling induced by extracellular stimuli. The first evidence has been provided by JY Wang et al. who reported activation of a cytoplasmic pool of c-Abl upon integrin engagement (Lewis et al., 1996) . Later, Pendergast et al. showed activation of cytoplasmic c-Abl upon growth factors stimulation (Plattner et al., 1999) . Since then, several reports have placed c-Abl in different cytoplasmic signalling cascades induced by various extracellular stimuli (Rhee et al., 2002; Woodring et al., 2003; Zipfel et al., 2004; Daniels et al., 2004; Ushio-Fukai et al., 2005; Noren et al., 2006) . Here, we will focus on the current understanding of the function of cytoplasmic c-Abl in growth factor receptor signalling and we will discuss its role in solid tumours as well.
Regulation of c-Abl
c-Abl function is tightly controlled in order to prevent oncogenic activity. Similarly to Src (Boggon & Eck, 2004) , c-Abl is regulated by intramolecular interactions that keep the kinase domain in a closed and inactive conformation (Figure 2 ). Strong evidences in favour of this self-inhibitory mechanism have been provided by recent structural and biochemical analysises which are discussed in detail by Hantschel and Superti-Furga (2004) . c-Abl closed conformation implicates the interaction between the SH3 domain and the Pro-rich sequence present in SH2-kinase linker (Barila & Superti-Furga, 1998) , as previously described for Src Williams et al., 1997; Xu et al., 1997) . Additionally, c-Abl regulation implicates unique interactions that involve the SH2 domain, the myristoylation site and the first 80 N-terminal amino acids of the 1b protein, that Pluk et al. named the "Cap" (Pluk et al., 2002; Hantschel et al., 2003; Nagar et al., 2003) . The SH2 domain interacts with the carboxyterminal lobe of the kinase domain, while the myristoyl binds to a deep hydrophobic pocket present in the same domain. An alternative mechanism is however suggested for the nonmyristoylated 1a isoform. The Cap region interacts with the SH3-SH2 connector and strengthens its clamp function to maintain the kinase domain in an inactive conformation hal-00346793, version 1 -12 Dec 2008 (Nagar et al., 2006 . All these interactions participate in the kinase auto-inhibition. Opening this conformation by any means is predicted to induce catalytic activation. Accordingly, SH2 and SH3 binders can induce c-Abl activation, and disruption of these interactions by mutation leads to transforming activity, as observed in oncogenic Abl alleles (Figure 1 ) (Hantschel & Superti-Furga, 2004) . Additionally, these data uncovers an unsuspected function for Nmyristoylation. This peptidic acylation is thought to be important for protein plasma membrane localisation (Resh, 1999) . However, in the present case, it does not modify c-Abl sub-cellular localisation but rather regulates its catalytic activity in vivo (Hantschel et al., 2003) .
This suggests that myristoyl-transferase/deacylases are potentially important regulators of Abl in vivo.
c-Abl is regulated also by phosphorylation. A phospho-proteomic analysis identified at least 12 phosphorylation sites on Tyr residues, all clustered in the N-terminus (Hantschel & Superti-Furga, 2004) . The function of Tyr245 and Tyr412 has been thoroughly analysed and mutagenesis has confirmed that these phosphorylation sites are required for c-Abl activation.
Nevertheless, the nature of the involved kinase(s) has not been clearly established. While cAbl may achieve phosphorylation in trans (Brasher & Van Etten, 2000; Dorey et al., 2001 ), other kinases could also ensure phosphorylation, the best candidates being SFK (Plattner et al., 1999; Dorey et al., 2001; Furstoss et al., 2002 ; Tanis et al., 2003) . Moreover, c-Abl is phosphorylated also on Ser and Thr residues that are involved in the catalytic regulation (Hantschel et al., 2003) . For example, a structural analysis identified a Ser residue in the Cap region that, upon phosphorylation by a yet unknown kinase, makes contact with the SH3-SH2
connector (Nagar et al., 2006) . Similarly, the Serine/Threonine p21-Activated Kinase 2 (PAK2) has been shown to interact with and activate c-Abl via phosphorylation of Ser637 and 638 (Jung et al., 2008) . Overall, these data suggest that phosphorylation is an important and complex way for the in vivo regulation of c-Abl.
Activation by growth factors
Cytoplasmic c-Abl is activated by various growth factors. For example, a 2 to 3 fold increase in its activaty has been observed in quiescent fibroblasts stimulated by PlateletDerived Growth Factor (PDGF) (Plattner et al., 1999) . A similar activation has been reported for Arg (Plattner et al., 2004) . Mutagenesis analysis has implicated two tyrosines present in the juxta-membrane region of the PDGF receptor (PDGFR), which, when phosphorylated, create a binding site for SFK. A role for these kinases has been confirmed by dominant hal-00346793, version 1 -12 Dec 2008
negative and pharmacological approaches (Plattner et al., 1999; Furstoss et al., 2002) .
Mechanistically, c-Abl forms a complex with activated SFK [ (Stanglmaier et al., 2003) and S.
Roche, unpublished data] and PDGFR, through its Src binding site (Plattner et al., 2004) .
Although the role of SFK in c-Abl binding to PDGFR has not been demonstrated, the existence of a ternary tyrosine kinase complex PDGFR/Src/c-Abl has been suggested, enabling Src-induced c-Abl phosphorylation and activation. c-Abl phosphorylation may be, however, reduced by the tyrosine phosphatase and c-Abl interactor PSTPIP1. Accordingly, PDGF-induced c-Abl phosphorylation is increased in cells deficient in PSTPIP1 (Cong et al., 2000) or in cells treated with vanadate, a general tyrosine phosphatase inhibitor (Furstoss et al., 2002) . (Woodring et al., 2001 ), a decrease in PIP 2 level could alleviate such inhibitory mechanism. We propose, however, an alternative route that implicates the lipid second messenger Sphingosine 1 Phosphate (S1P) (Veracini et al., 2006) . By associating with a seven transmembrane receptor encoded by endothelial differentiation genes (EDG), collectively known as the S1P-receptors, S1P may activate a heterotrimeric Gi protein/Src pathway allowing c-Abl activation. Interestingly, PDGF-induced S1P accumulation requires PLCγ (Olivera et al., 1999) , which may explain, at least in part, the role of this phospholipase in c-Abl activation. How PDGF uses both Src and a PLCγ for c-Abl activation is not clearly established. One hypothesis involves the existence of two distinct cytoplasmic pools of c-Abl.
Accordingly, the use of fluorescent reporters of c-Abl activities has uncovered two distinct populations in PDGF-stimulated cells: the first is associated with cytoplasmic structures and the second is concentrated in membrane ruffles (Ting et al., 2001) . Interestingly, a similar situation has been reported for SFK with a pool present in the cholesterol-enriched plasma membrane domains caveolae, which regulates its association with the receptor, and another one associated with F-actin enriched ruffles that is regulated by PLCγ (Veracini et al., 2006 receptor and c-Abl in actinic structure through S1P signalling. Such activities may in turn induce distinct signalling cascades and cellular responses (Veracini et al., 2006) . c-Abl is also activated by members of the EGF receptor (EGFR) family (Jones et al., 2006; Plattner et al., 1999) . The molecular mechanism underlying this process remains elusive. EGFR does not associate with SFK, whose role in c-Abl activation is questionable.
Rather, activation may implicate an AblSH2-pTyr interaction. This hypothesis is supported by the finding of a high affinity binding site for AblSH2 in all members of the EGFR family (ErbB1-4) (Jones et al., 2006) . Interestingly, these interactions have been observed in a high throughput protein micro array study, even though they were not predicted by Scansite in silico analysis. Consistent with this notion, c-Abl has been found co-associated with these receptors in various cell lines (Jones et al., 2006; Srinivasan & Plattner, 2006) . We thus believe that EGFR activation may create an Abl-SH2 binding site that stabilises the kinase in an open and active conformation, a mechanism previously reported for PDGFR-induced Src activation.
c-Abl is also activated by mitogenic receptors of the non-tyrosine kinase type. These include Transforming Growth Factor beta (TGF-β) (Daniels et al., 2004; Wang et al., 2005) and Angiotensin subtype 1 (AT-1) receptors (Ushio-Fukai et al., 2005) . TGF-β receptor is a Serine/Threonine kinase that uses adapters of the Smad family for signalling (Schmierer & Hill, 2007) . However, in a subset of mesenchymal cells, it also induces c-Abl activation, via a mechanism independent of the Smad pathway. In these cells, c-Abl activation requires phosphoinositide 3' kinase (PI3K) activity and the Rac effector PAK2 (Wilkes & Leof, 2006) . 
c-Abl cytoplasmic signalling in normal cells

Mitogenesis
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Activation of cytoplasmic c-Abl plays important roles in cellular responses induced by growth factors, including promotion of DNA synthesis, F-actin assembly and receptor trafficking. Previous reports assigned a negative function for c-Abl during cell proliferation (Sawyers et al., 1994; Wen et al., 1996) . However, c-Abl appears to have antagonistic function depending on its sub-cellular localisation. Accordingly, nuclear c-Abl can induce a G1 phase block of the cell cycle, while cytoplasmic c-Abl can promote mitogenesis (Vigneri & Wang, 2001 ). The positive mitogenic role of cytoplasmic c-Abl has been uncovered in Abl deficient cells. These cells exhibit a 4-6 hour delay in DNA synthesis following PDGF and serum induction (Plattner et al., 1999; Furstoss et al., 2002) . The specific function of cytoplasmic c-Abl has been further confirmed by targeting its cytoplasmic activity without affecting the nuclear function. This has been achieved by microinjection of neutralising antibodies in the cytoplasm or expression of dominant negative, cytoplasmic forms of c-Abl (Furstoss et al., 2002) . In both situations, mitogenesis was inhibited. This set of experiments has led to the conclusion that cytoplasmic c-Abl is required during mitogenesis. c-Abl has been then identified as an important effector of Src for mitogenic signalling (Furstoss et al., 2002) , which is required for DNA synthesis (Figure 3 ). Src signalling does not impact on Ras activity, but rather induces a unique cascade that culminates in c-myc induction, important for DNA synthesis initiation (Bromann et al., 2004) . Hence, growth factors such as PDGF use a tyrosine kinase signalling cascade (i.e., receptor/Src/c-Abl) to promote DNA synthesis.
c-Abl mitogenic substrates have not yet been identified, but they are likely to include regulators of small GTPases of the Rho family, especially Vav and Sos members (Matsuguchi et al., 1995; Chiariello et al., 2001; Sini et al., 2004) . This notion is supported by the identification of the small GTPase Rac as an important transducer of Src/c-Abl and v-Abl mitogenic signals (Renshaw et al., 1996; Boureux et al., 2005) . Rac further propagates signalling via the induction of NADPH oxidase and Jun N-terminal Kinase (JNK) activities to favour c-myc induction and cell cycle progression (Boureux et al., 2005) . Abl kinases have important functions in actin cytoskeleton reorganisation. Their role in morphological processes has been illustrated by the significant defect in the actin latticework of Abl/Arg -/-mouse embryos (Koleske et al., 1998) . In tissue culture models, Abl kinases regulate F-actin organisation needed for lamellipodia, filopodia and neurite extension.
These morphological changes mediate cell adhesion, migration and neurogenesis (Woodring et al., 2003) . Upon growth factor stimulation, a fraction of active c-Abl is localised at sites of F-actin assembly where lateral ruffles are formed (Ting et al., 2001) . It is believed that c-Abl might participate in this process, when promoted by EGF and PDGF, but the associated mechanism has not been further investigated (Sini et al., 2004; Sossey-Alaoui et al., 2007; Stuart et al., 2006) . Additionally, c-Abl co-localises with F-actin structures at the dorsal surface of the cell, where circular ruffles are formed. These ruffles are also called waves because of their transient assembly (Buccione et al., 2004) . The role of this actinic rearrangement has been puzzling for several decades as it could be specific of the culture conditions. Nonetheless, it has been suggested to be an emanation of a motile state induction, including cytoplasmic remodelling and establishment of cell polarity. Since then, dorsal ruffles have been linked to various cellular processes, including macro-pinocytosis (Dowrick et al., 1993; Dharmawardhane et al., 2000) , receptor endocytosis (Orth et al., 2006) and cell invasion (Suetsugu et al., 2003) . While EGF and Hepatocyte Growth Factor (HGF) can induce waves in certain conditions, PDGF seems to be the most potent inducer, specifically in fibroblast-like cells. These signalling cascades have been partially elucidated and they implicate c-Abl. Indeed, fibroblasts from Abl/Arg-/-mouse embryos show a 8 fold reduction in dorsal ruffles formation (Plattner et al., 1999; Furstoss et al., 2002) . Similar results have been obtained also with dominant negative approaches (Veracini et al., 2006) . For this cellular response, PDGF may recruit an actinic pool of c-Abl activity which is induced by a S1P/Src pathway (Veracini et al., 2006) . Therefore, PDGF uses a spatially regulated tyrosine kinase signalling cascade for F-actin organisation.
How Abl kinases regulate dorsal ruffles has been partially unravelled (Figure 4 ). c-Abl may function upstream, downstream and in parallel to Rac, a key regulator of F-actin assembly. A role for c-Abl upstream of Rac has been evidenced by the strong reduction of PDGF-induced Rac activation observed in c-Abl deficient cells (Sini et al., 2004; Boureux et al., 2005) . However, it is yet unknown whether this reduction is linked to the pool of Rac involved in mitogenic signalling and/or in F-actin assembly. c-Abl is thought to regulate Rac activity by phosphorylation and activation of a Rac-specific Guanine Nucleotide Exchange
Factor (Ras-GEF), a likely candidate being SOS-1. This Ras-GEF shows a specific activity towards Rac when in a complex with the PI3K, Eps8 and Abi-1 adaptors (Innocenti et al., 2002; Innocenti et al., 2003) . Moreover, phosphorylation of SOS-1 by c-Abl increases this Rac specific activity (Sini et al., 2004) . Dynamin, Cortactin orchestrates F-actin assembly (Krueger et al., 2003) . While c-Abl phosphorylation is required for Cortactin function (Boyle et al., 2007) , the underlying mechanism is currently unknown. In summary, these data reveal a complex, but important, role for c-Abl in F-actin assembly leading to dorsal ruffle formation.
Cell migration
c-Abl plays important functions in F-actin dynamics, yet its role in growth factorinduced cell motility is ill defined. An inhibitory role has been originally described during cell adhesion and migration when induced by the extracellular matrix. Accordingly, c-Abl increases F-actin microspikes, but reduces cell spreading, thus revealing a sensory function during cell adhesion (Woodring et al., 2002) . A negative role has been suggested in cells stimulated by Collagen (Kain & Klemke, 2001 ) and HGF (Kain et al., 2003) , been reported in breast carcinomas (Srinivasan & Plattner, 2006) and anaplastic thyroid cancers (Podtcheko et al., 2003) ; furthermore, Arg over-expression has been correlated with colon carcinoma progression (Chen et al., 1999) . Over-expression of c-Abl is however not sufficient and constitutive kinase activity requires protein phosphorylation. For instance, Srcinduced c-Abl phosphorylation increases its cytoplasmic kinase activity by 10 folds (Plattner et al., 1999) . In breast cancer cells, c-Abl phosphorylation is induced by plasma membrane tyrosine kinases including SFK, EGFR family members and Insulin Growth factor I Receptor (IGFI-R) (Srinivasan & Plattner, 2006; Sirvent et al., 2007; Srinivasan et al., 2007) .
Additional kinases might be involved in this process, such as the oncogenic receptor tyrosine kinase RET/ Papillary thyroid cancers 3 (PTC3) (Iavarone et al., 2006) . While Abl fusion proteins have not been detected in solid cancers, recent data indicate that deregulation could be also caused by a genetic mechanism. This notion is supported by two high through-put genomic analyses of a large set of tumours and cancer cell lines (Greenman et al., 2007; Ruhe et al., 2007) . These studies have allowed the identification of somatic mutations and/or sequence deletions in c-Abl transcripts. Interestingly, most of them are clustered in the Cap region, the SH2 and the kinase domains. Due to the important roles of these domains in catalytic auto-inhibition, these alleles might generate oncogenic Abl kinases. These mutations have been detected in skin, ovary, prostate, and colon tumours in addition to lung and breast cancers. It should be stressed that these genetic alterations are rare, an observation which supports the notion that c-Abl deregulation in these cancers primarily involves kinase phosphorylation/activation by upstream oncogenic tyrosine kinases.
Neoplastic transformation
Cytoplasmic c-Abl has been recently implicated in neoplastic transformation ( Figure   5 ). For example, we have demonstrated the requirement of cytoplasmic c-Abl in Src transforming activity. c-Abl function depends on its kinase activity, implying phosphorylation of Tyr245 and Tyr412 (Sirvent et al., 2007) . Surprisingly, catalytic activation also requires PI3K and PLC activities, suggesting a role for phosphoinositides in this biochemical process (S. Roche, unpublished data). In addition to Rac/JNK signalling, c-Abl induces an Extracellular Regulated Kinase 5 (ERK5) pathway necessary for maximal transforming activity (Sirvent et al., 2007) . c-Abl induces ERK5 by protein stabilisation (Buschbeck et al., 2005) and/or catalytic activation (Sirvent et al., 2007) by a yet unknown mechanism. This pathway impacts on cell cycle progression via c-fos and Cyclin D induction (Kato et al., 1997; hal-00346793, version 1 -12 Dec 2008 involved in cell transformation. Interestingly, an additional Abl/ERK8 pathway has been identified upon expression of the oncogenic tyrosine kinase RET/PTC3 (Iavarone et al., 2006) , but the biological significance of ERK8 activation in oncogenesis remains elusive. cAbl also regulates cell transformation induced by Serine/Threonine kinases. For instance, inhibition of Abl kinases abrogates the capacity of TGF-β to induce anchorage-independent growth of human fibroblasts (Wilkes & Leof, 2006) . In this context, Integrins and Collagen expression are under the control of c-Abl, which may influence this cellular response. Abl kinases also regulate human cancer cell growth. This notion has been confirmed in cell lines from breast and anaplastic thyroid tumours (Podtcheko et al., 2003) . Interestingly, c-Abl requirement has been mostly observed in breast cancer cells whose growth is dependent on SFK activities. Cell growth is under the control of Abl/Rac and Abl/ERK5 signalling pathways (Sirvent et al., 2007) . Additionally, a role for c-Abl has been also proposed for the activation of Stat1 and Stat3 transcription factors (Srinivasan et al., 2007) , which are important for breast cancer progression. However, the effect of c-Abl on Stat oncogenic activity has not been determined in these cells. Finally, c-Abl seems to be required for DNA synthesis induced by IGF-1 (Srinivasan et al., 2007) .
Epithelial to Mesenchymal transition (EMT) and cell invasion
Abl kinases play important roles in cancer cell migration and invasion. Yang et al (2006) have documented an unanticipated role for cytoplasmic c-Abl in EMT. This cellular process includes loss of cell polarity and cell-cell contact followed by induction of a fibroblastoid morphology which is required for cell motility. EMT plays an important role during embryogenesis and possibly during cancer invasion (Thiery & Sleeman, 2006) . In colon cancer cells, PDGF-induced EMT requires c-Abl activation. While not tested, Src may probably mediate this activation, since mutation of Src phosphorylation sites prevents EMT.
Using a proteomic approach, Yang et al. (2006) have identified the p68 RNA helicase (p68) as an important substrate of c-Abl signalling. β-catenin is a key player in this process (Brembeck et al., 2006) . In non stimulated cells, β-catenin is concentrated at adherent 6). Interestingly, the c-Abl/p68 axis seems to operate upon EGF and TFG-β stimulation and in non transformed cells as well, suggesting that it is a general and conserved pathway for EMT induction (Yang et al., 2006) . Additionally, c-Abl can activate β-catenin function by direct phosphorylation, as demonstrated following activation of the Robo receptor (Rhee et al., 2002) and as suggested in anaplastic thyroid cancer cells (Rao et al., 2006) . Finally, c-Abl can interact with the cytoplasmic tyrosine kinase Pyk2 to promote breast cancer cell migration (Zrihan-Licht et al., 2004) . All this data predict a positive role for cytoplasmic c-Abl in neoplastic cell invasion. Indeed, c-Abl has been shown to regulate the invasive activity of aggressive breast cancers (Srinivasan & Plattner, 2006) and some thyroid cancer cells (Rao et al., 2006) . Surprisingly, cytoplasmic c-Abl can also have a negative effect on neoplastic cell Several of them have been now developed, such as the dual Src/Abl inhibitor Dasatinib (Lombardo et al., 2004; Tokarski et al., 2006) . In addition to leukaemias, this compound is expected to give a significant therapeutic response in solid tumours, especially those showing oncogenic Src/Abl activities, including lung and breast cancers. Indeed, a large phosphoproteomic survey has identified a subset of non small cell lung cancers with strong Src/Abl activities (Rikova et al., 2007) . In the case of breast cancer, two independent studies have hal-00346793, version 1 -12 Dec 2008 identified a subset of cancer cells with high sensitivity to Dasatinib (Finn et al., 2007; Huang et al., 2007) . Those are mainly cells of basal origin that went through EMT and are triple negative for oestrogen, progesterone and ErbB2 receptors. This type of cancers has a poor prognosis and strong resistance to current therapy. Moreover, genomic analyses have delineated a molecular signature for Dasatinb sensitivity, that, remarkably, has been observed in other breast, lung and ovary primary tumours (Huang et al., 2007) , predicting an activity of Dasatinib also in these cancers.
While not yet validated in clinical studies, these observations suggest that targeting the Src/Abl oncogenic signalling cascade will be also of therapeutic value in solid cancers.
Concluding Remarks
Although c-Abl was identified more than 30 years ago (Wang et al., 1984) , its role in cytoplasmic signalling has emerged only recently. This may be due to the assigned activity of 
